All existing investors, including Third Rock Ventures, GV, SR One, and Regeneron Pharmaceuticals, participated in the round, and were joined by new investors including Foresite Capital, Bessemer Trust,
BridgeBio also announced that it has launched a subsidiary company Fortify Therapeutics to further develop this chemistry for local treatment of Leber's Hereditary Optic Neuropathy (LHON), with an
The designation is for the treatment of patients with medium to high folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer who received at least one, but no more than
Celltrion submitted its abbreviated Biologics License Applications (aBLAs) for CT-P10 and CT-P6 to the FDA in April and May of last year, respectively. However, it received CRLs (complete
The trial showed a statistically significant and clinically meaningful improvement in progression-free survival (PFS) for patients treated with EPd compared with pomalidomide and dexamethasone (Pd) alone. ELOQUENT-3 is
Top-line trial data were previously reported on 8 May 2018 and an update was provided on 11 May 2018. The biomarker data confirms that Traumakine treatment did not
Sage received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for SAGE-217 in MDD in February 2018, and recently announced an expedited development plan for
The acquisition of Sanofi’s manufacturing centre and business located in Holmes Chapel provides Recipharm with a solid platform to take further advantage of the growing respiratory drug market.
Roche chief medical officer and global product development head Sandra Horning said: “Today’s approval is an important advance for women newly diagnosed with this type of ovarian cancer.
These two trials, KF7013-02 and KF7013-04, are investigating the efficacy and safety of neridronate in 360 patients with CRPS. Neridronate, a bisphosphonate, is an innovative investigational medicine discovered
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.